中信證券(06030.HK)擬為間接全資子公司最高30億美元歐洲商業票據計劃提供擔保
格隆匯5月15日丨中信證券(06030.HK)公吿,經公司第七屆董事會第二十一次會議預審同意、公司2020年度股東大會決議,公司股東大會再次授權公司發行境內外公司債務融資工具。
根據上述授權,公司境外全資子公司中信證券國際有限公司的附屬公司CITIC Securities Finance MTN Co.,Ltd.(以下簡稱發行人或被擔保人)於2023年5月12日更新設立本金總額最高為30億美元(或等值其他貨幣)的境外歐洲商業票據計劃(以下簡稱商業票據計劃),此票據計劃由公司提供擔保。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.